Elixir Pharmaceuticals plans $86.25 mln IPO

WASHINGTON, Sept 21 (Reuters) - Elixir Pharmaceuticals Inc, which focusses on treating metabolic diseases such as diabetes and obesity, said on Friday it is planning an initial public offering of up to $86.25 million in common stock.

It has hired Credit Suisse, Pacific Growth Equities LLC and Leerink Swann to underwrite the IPO, according to a preliminary offering document filed with the Securities and Exchange Commission.

The Cambridge, Massachusetts-based company is seeking a Nasdaq listing under the symbol "ELXR."